Epstein-Barr virus peptide-Human Leukocyte Antigen complexes (EBV pHLA) (EBV pHLA)

Peptide-HLA complexes derived from Epstein-Barr virus (EBV) proteins, specifically Latent Membrane Protein 2 (LMP2), EBV Nuclear Antigen 1 (EBNA1), and the lytic protein BZLF1, are essential targets for immunotherapeutic intervention in EBV-associated diseases (Bollard & Heslop, 2016). These complexes consist of short viral peptide sequences bound within the groove of Human Leukocyte Antigen (HLA) molecules on the surface of infected cells, serving as the primary signal for T-cell recognition (Taylor et al., 2015). LMP2 and EBNA1 are frequently expressed in latency patterns associated with malignancies such as nasopharyngeal carcinoma and Hodgkin lymphoma, while BZLF1 is a key mediator of the viral lytic cycle (Haque et al., 2007). Therapeutic approaches, including adoptive T-cell transfer and TCR-engineered T-cells, leverage these complexes to direct the immune system to selectively destroy EBV-positive tumor cells (Prock et al., 2023). For instance, tabelecleucel is an allogeneic T-cell therapy designed to recognize these specific pMHC targets in patients with post-transplant lymphoproliferative disorder (Ebvallo Summary of Product Characteristics, 2022). Because these targets are exclusively viral, they provide a high degree of tumor specificity, minimizing the risk of off-target toxicity against healthy host tissues.

Other names

EBV-specific MHC-peptide complexesEBV pMHCLMP2-HLA complexEBNA1-HLA complexBZLF1-HLA complexEBV-derived peptide-HLA complexes

T-cell receptor (TCR) mediated recognition of specific viral peptides presented on HLA molecules, leading to the targeted cytotoxic lysis of EBV-infected or malignant cells.